Welcome to our dedicated page for Neuropace news (Ticker: NPCE), a resource for investors and traders seeking the latest updates and insights on Neuropace stock.
NeuroPace Inc (NPCE) is a pioneering medical technology company developing brain-responsive neuromodulation systems for epilepsy treatment. This page serves as the definitive source for official company announcements, financial updates, and clinical progress reports.
Access timely updates on NPCE's innovative RNS System, including FDA regulatory milestones, partnership developments with leading epilepsy centers, and peer-reviewed clinical study results. Investors will find earnings reports and strategic initiatives, while healthcare professionals can track real-world treatment outcomes and technological refinements.
Our curated news collection features:
- Quarterly financial performance updates
- RNS System enhancement announcements
- Clinical trial data publications
- Regulatory clearance milestones
- Research collaborations with medical institutions
Bookmark this page for structured access to NPCE's evolving role in neurotechnology and epilepsy care innovation.
NeuroPace (NPCE) has completed its public offering of 7,475,000 shares of common stock at $10.00 per share, including 975,000 shares from the underwriters' option exercise. The offering generated gross proceeds of $74.8 million.
The company plans to use $49.5 million to repurchase 5,270,845 shares from KCK at $9.40 per share. The remaining proceeds will fund general corporate purposes, including clinical trials, R&D, administrative expenses, debt reduction, and working capital.
The offering was managed by J.P. Morgan, Cantor, Wells Fargo Securities, and Leerink Partners as joint book-running managers, with Lake Street Capital Markets as lead manager.
NeuroPace (NPCE) has announced the pricing of a public offering of 6.5 million shares of common stock at $10.00 per share, expecting to raise $65 million in gross proceeds. The offering, set to close on February 18, 2025, includes a 30-day option for underwriters to purchase up to 975,000 additional shares.
The company plans to use $49.5 million of the net proceeds to repurchase approximately 5.27 million shares from KCK at $9.40 per share. The remaining proceeds will fund general corporate purposes, including clinical trials, R&D expenses, administrative costs, debt reduction, and working capital.
The offering is managed by J.P. Morgan, Cantor, Wells Fargo Securities, and Leerink Partners as joint book-running managers, with Lake Street Capital Markets as lead manager.
NeuroPace (NPCE) has announced plans for a $65 million public offering of common stock, with an additional 30-day option for underwriters to purchase up to 15% more shares. A substantial portion of the proceeds will be used to repurchase all shares held by KCK , a significant stockholder, at the same price per share as the public offering.
The remaining proceeds will fund general corporate purposes, including clinical trials, R&D expenses, selling, general and administrative expenses, debt reduction, and working capital. The offering's joint book-running managers are J.P. Morgan, Cantor, Wells Fargo Securities, and Leerink Partners, with Lake Street Capital Markets as lead manager.
The offering will be made through a shelf registration statement previously declared effective by the SEC on November 22, 2022.
NeuroPace (NPCE), a medical device company specializing in epilepsy treatment, announced that data from their RNS System Post-approval Study will be presented at the American Academy of Neurology (AAN) 2025 Annual Meeting. The presentation, titled 'Multicenter Post-approval Study of the RNS System in Focal Epilepsy,' will be delivered by Dr. Dawn Eliashiv, Professor of Neurology and Co-Director of UCLA Seizure Disorders Center. The session is scheduled for Monday, April 7th, at 5:06 PM PT during the Epilepsy Clinical Outcomes and Prognostication session at the conference being held in San Diego from April 5th to 9th.
NeuroPace (NPCE) has announced its 2025 financial guidance and three-year strategic objectives. The company projects 2025 revenue between $92-96 million, representing 15.5-20.5% growth from 2024's expected range of $79.4-79.9 million. The gross margin target is set at 73-75%, with total operating expenses projected at $92-95 million, including $11 million in stock-based compensation.
The company's three-year strategic plan aims to establish NeuroPace as the leader in drug-resistant epilepsy therapy, targeting a 20%+ revenue CAGR. Key objectives include expanding indications to Idiopathic Generalized and Pediatric drug-resistant epilepsy patients, advancing AI tools and remote programming capabilities, enhancing patient awareness through direct-to-consumer campaigns, and achieving cash flow breakeven.
NeuroPace (NPCE) announced preliminary unaudited Q4 2024 revenue between $21.0-21.5 million, representing 17-19% growth versus Q4 2023. Full-year 2024 revenue is expected between $79.4-79.9 million, showing 21-22% growth compared to 2023 and exceeding initial guidance of $73-77 million.
The company reported cash and short-term investments of $52.8 million as of December 31, 2024, with 30,145,039 total shares outstanding. The NAUTILUS pivotal trial, evaluating RNS System for drug-resistant idiopathic generalized epilepsy, is on track to complete one-year follow-up in March 2025.
Scott Huennekens was appointed to NeuroPace's Board of Directors effective January 6th, 2025. The company will present at the J.P. Morgan Healthcare Conference on January 15th and host an Investor Day on January 28th in New York City.
NeuroPace (NPCE), a medical device company specializing in epilepsy treatment solutions, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The company's management team will deliver a presentation on January 15, 2025, at 4:30 PM PT (7:30 PM ET) in San Francisco, CA.
In addition to the presentation, the management team will engage in investor meetings throughout the conference. Interested parties can access the presentation through a live webcast, and a replay will remain available for two weeks following the event on the Events section of NeuroPace's Investor website.
NeuroPace (NPCE), a medical device company specializing in epilepsy treatment, has announced an upcoming Investor Day scheduled for January 28, 2025, in New York City. The event will run from 9:00 a.m. to 12:00 p.m. ET.
The presentation will showcase the company's RNS technology and future strategic plans. Management will discuss recent results and outline market, product, and clinical development strategies for the RNS System. The event will feature presentations from clinical key opinion leaders and include personal testimony from an RNS patient about their experience with the system.
NeuroPace (NASDAQ: NPCE) announced its participation in the 2024 American Epilepsy Society Annual Meeting (AES 2024) at the Los Angeles Convention Center from December 6-10, 2024. The company's RNS System will be featured in over 70 scientific presentations and posters.
At booth #2119, NeuroPace will showcase their responsive neuromodulation technology, highlighting 82% seizure reduction at three years and improved quality of life without chronic side effects common in other neuromodulation therapies. The company is hosting demonstrations, panels, and networking events, including a Fellows Networking Reception and a Product Theater presentation on 'New Frontiers in Responsive Neuromodulation.'
NeuroPace announced completion of enrollment and implant procedures in its feasibility IDE study of the RNS System for treating Lennox-Gastaut Syndrome (LGS), a severe childhood-onset epilepsy. The study, funded by a $9.3 million NIH grant, enrolled 20 patients aged 12 and older across six sites to evaluate the safety and effectiveness of brain-responsive stimulation for LGS treatment.
The study includes a one-year open label period followed by an 18-month long-term follow-up. LGS affects patients severely, with 85% continuing to have seizures into adulthood, 98% suffering from intellectual disability, and affected individuals being 12 times more likely to die prematurely than their peers.
